Micheal Hall
Family Medicine · Los Angeles, CANPI 1396744850
Payments from drug & device makers
Across 137 payments — averaging $48.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$5K
- Gilead$639
- EMD Serono, Inc.$388
- Napo Pharmaceuticals Inc$180
- Johnson & Johnson$164
- Merck$81
- plus $318 from 9 others
What the payments were for
- Consulting fees$3,68056%
- Speaking & faculty fees$331%
- Travel & lodging$310%
- Food & beverage$2,85743%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 62 | $4,833 |
| Gilead | 20 | $639 |
| EMD Serono, Inc. | 13 | $388 |
| Napo Pharmaceuticals Inc | 12 | $180 |
| Johnson & Johnson | 12 | $164 |
| Merck | 5 | $81 |
| Stryker | 1 | $67 |
| Theratechnologies Inc. | 2 | $59 |
| Lilly USA, LLC | 3 | $52 |
| AbbVie | 2 | $42 |
| Janssen Scientific Affairs, LLC | 1 | $24 |
| Mylan Institutional Inc. | 1 | $21 |
| Antares Pharma, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $19 |
| Pfizer | 1 | $15 |
How this compares
$6,601 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 213 | $794,057 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 82 | $359,831 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 70 | $257,524 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 66 | $252,131 |
| TivicayDolutegravir Sodium | 91 | $193,708 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 52 | $188,696 |
| DescovyEmtricitabine/Tenofov Alafenam | 86 | $182,436 |
| CabenuvaCabotegravir/Rilpivirine | 27 | $168,903 |
| JulucaDolutegravir/Rilpivirine | 34 | $117,997 |
| IsentressRaltegravir Potassium | 48 | $89,773 |
| PrezcobixDarunavir/Cobicistat | 32 | $75,901 |
| TrulicityDulaglutide | 44 | $47,373 |
| DovatoDolutegravir Sodium/Lamivudine | 17 | $46,119 |
| CompleraEmtricita/Rilpivirine/Tenof Df | 11 | $39,216 |
| Etravirine | 25 | $25,956 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $639 | $1,228,624365 claims |
| Viiv Healthcare CompanyTivicay, Triumeq, Cabenuva, Juluca, Dovato | $4,833 | $715,423221 claims |
| Johnson & JohnsonPrezcobix, Complera | $164 | $115,11743 claims |
| MerckIsentress, Januvia | $81 | $110,52789 claims |
| Lilly USA, LLCTrulicity | $52 | $47,37344 claims |
| Janssen Scientific Affairs, LLCEdurant | $24 | $20,59216 claims |
| Novo NordiskRybelsus | $19 | $19,71021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Los Angeles
- Albert NassirLos Angeles$5.7M
- Nader SobhLos Angeles$4.1M
- Alexander RivkinLos Angeles$2.8M
- Pamela KushnerLos Angeles$1.2M
- Scott HowellLos Angeles$793K
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.